[Enprostil in the acute treatment of duodenal ulcer: direct comparative study with pirenzepin].
In a randomized, endoscopically controlled double-blind trial the effectiveness of a twice daily dose of the prostaglandin E2-analogue enprostil was compared with pirenzepine given to 97 ambulatory patients with duodenal ulcers. Under 35 micrograms b.i.d. enprostil the ulcer healing rates after 2, 4 and 6 weeks averaged 41%, 82% and 92%. The corresponding values for pirenzepine were 44%, 72% and 89%. The differences were not statistically significant. Both drugs had a similar influence on the ulcer symptoms.
D000208:Acute Disease; D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001570:Benzodiazepinones / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000188:drug therapy*; D016620:Enprostil; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010890:Pirenzepine; D011459:Prostaglandins E, Synthetic / Q000627:therapeutic use*; D011897:Random Allocation; D012907:Smoking; D014945:Wound Healing
D000897:Anti-Ulcer Agents; D001570:Benzodiazepinones; D011459:Prostaglandins E, Synthetic; D010890:Pirenzepine; D016620:Enprostil
Enprostil in der Akutbehandlung des Ulcus duodeni: Eine direkte Vergleichsstudie mit Pirenzepin.